15384-39-1

Basic information

• Product Name: (3-Methoxy-phenyl)-hydrazine
• Synonyms: (3-Methoxy-phenyl)-hydrazine;m-Methoxyphenylhydrazine;Hydrazine, (3-methoxyphenyl)-
• CAS NO: 15384-39-1
• Molecular Formula: C₇H₁₀N₂O
• Molecular Weight: 138.17
• Product Categories: Benzene series
• Mol File: 15384-39-1.mol

Chemical Properties

• Melting Point: 59-60 °C
• Boiling Point: 275℃
• Flash Point: 120℃
• Appearance: /
• Density: 1.150
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 5.41±0.10(Predicted)
• CAS DataBase Reference: (3-Methoxy-phenyl)-hydrazine(CAS DataBase Reference)
• NIST Chemistry Reference: (3-Methoxy-phenyl)-hydrazine(15384-39-1)
• EPA Substance Registry System: (3-Methoxy-phenyl)-hydrazine(15384-39-1)

Safety Data

• Hazardous Substances Data: 15384-39-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(3-Methoxy-phenyl)-hydrazine is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs and improve the efficacy of existing ones.
Used in Agrochemical Industry:
In the agrochemical sector, (3-Methoxy-phenyl)-hydrazine is utilized as an intermediate in the production of agrochemicals, helping to create compounds that protect crops and enhance agricultural productivity.
Used in Dye and Pigment Industry:
(3-Methoxy-phenyl)-hydrazine is employed as an intermediate for the preparation of dyes and pigments, contributing to the creation of a wide range of colors used in various industries, such as textiles, plastics, and printing.
Safety Precautions:

Upstream product

• 536-90-3 m-Anisidine 
• 39232-91-2 m-methoxyphenylhydrazine hydrochloride 
• 3899-92-1 3-methoxyphenyl 4-methylbenzenesulfonate 
• 2845-89-8 1-chloro-3-methoxy-benzene 
• 766-85-8 3-methoxy-1-iodobenzene 

Downstream Products

• 68962-14-1 1,2,3,4-tetrahydro-5-methoxycarbazole 
• 3382-43-2 7-methoxy-2,3,4,9-tetrahydro-1H-carbazole 
• 372093-71-5 6-methoxy-3-methyl-2-phenylindole 
• 109596-28-3 1-(3-methoxy-phenylhydrazono)-1,2,3,4-tetrahydro-quinolizinylium; iodide 
• 109648-93-3 1-(3-methoxy-phenylhydrazono)-1,2,3,4-tetrahydro-quinolizinylium; bromide 
• 58176-56-0 6-methoxy-2,3-dimethyl-1H-indole 
• 97881-50-0 (1-Phenylmercapto-aceton)-3-methoxy-phenylhydrazon 
• 93896-38-9 (1-Ethoxycarbonylmethylmercapto-aceton)-3-methoxy-phenylhydrazon 
• 93988-08-0 Phenylmercaptoacetaldehyd-(3-methoxy-phenylhydrazon) 
• 103973-43-9 deoxybenzoin m-methoxyphenylhydrazone 
• 113575-81-8 C₁₂H₁₇N₃OS 
• 141502-64-9 C₁₂H₁₇N₃OS 
• 97456-64-9 3-methoxyphenylhydrazone of 2,3-piperidinedione 
• 107752-47-6 2-<2-(3-methoxyphenyl)hydrazino>tropone 

Relevant articles and documents

Visible-light-mediated phosphonylation reaction: formation of phosphonates from alkyl/arylhydrazines and trialkylphosphites using zinc phthalocyanine

In this work, we developed a ligand- and base-free visible-light-mediated protocol for the photoredox syntheses of arylphosphonates and, for the first time, alkyl phosphonates. Zinc phthalocyanine-photocatalyzed Csp2-P and Csp3-P bond formations were efficiently achieved by reacting aryl/alkylhydrazines with trialkylphosphites in the presence of air serving as an abundant oxidant. The reaction conditions tolerated a wide variety of functional groups.

Diversification of edaravone via palladium-catalyzed hydrazine cross-coupling: Applications against protein misfolding and oligomerization of beta-amyloid

N-Aryl derivatives of edaravone were identified as potentially effective small molecule inhibitors of tau and beta-amyloid aggregation in the context of developing disease-modifying therapeutics for Alzheimer's disease (AD). Palladium-catalyzed hydrazine monoarylation protocols were then employed as an expedient means of preparing a focused library of 21 edaravone derivatives featuring varied N-aryl substitution, thereby enabling structure-activity relationship (SAR) studies. On the basis of data obtained from two functional biochemical assays examining the effect of edaravone derivatives on both fibril and oligomer formation, it was determined that derivatives featuring an N-biaryl motif were four-fold more potent than edaravone.

Structure-based design and biological evaluation of novel 2-(indol-2-yl) thiazole derivatives as xanthine oxidase inhibitors

Inhibition of xanthine oxidase (XO) has obviously been a central concept for controlling hyperuricemia, which causes serious and painful inflammatory arthritis disease such as gout. We discovered a series of novel 2-(indol-2-yl)thiazole derivatives as XO inhibitors at the level of nanomolar activity. Structure-guided design using molecular modeling program (Accelrys Software program) provided an excellent basis for optimization of 2-(indol-2-yl)thiazole compounds. Structure-activity relationship indicated that hydrophobic alkoxy group (isopropoxy, cyclopentoxy) at 5-position and hydrogen binding acceptor (NO2, CN) at 7-position of indole ring appear as critical functional groups. Among the compounds, 2-(7-nitro-5-isopropoxy-indol-2-yl)-4-methylthiazole-5-carboxylic acid (9m) exhibits the most potent XO inhibitory activity (IC50value: 5.1 nM) and the excellent uric acid lowering activity in potassium oxonate induced hyperuricemic rat model.

Synthesis of 1-(1-aryl-1H-1,2,3-triazol-4-yl)-β-carboline derivatives

Reaction of 5-methyl-1-aryl-1H-1,2,3-triazole-4-carbocylic acid chlorides with tryptamine derivatives afforded substituted 1-aryl-N-[2-(1H-indol-3-yl) ethyl]-5-methyl-1H-1,2,3-triazole-4-carboxamides. At heating these compounds in toluene in the presence of POCl3 and P2O5 Bischler-Napieralski cyclization occurs giving 1-(1-aryl-5-methyl-1H-1,2,3- triazol-4-yl)-4,9-dihydro-3H-β-carbolines that can be transformed into β-carboline and tetrahydro-β-carboline derivatives.

Efficient synthesis of aryl hydrazines using copper-catalyzed cross-coupling of aryl halides with hydrazine in PEG-400

An efficient and convenient method for the synthesis of aryl hydrazines is described via copper-catalyzed cross-coupling of aryl halides with aqueous hydrazine in PEG-400. This protocol is applicable to both electron-deficient and electron-rich aryl iodides and bromides, and even to sterically hindered substrates, giving aryl hydrazines in good to excellent yields.

Mild and rapid Pd-catalyzed cross-coupling with hydrazine in continuous flow: Application to the synthesis of functionalized heterocycles

Minimizing risk: The synthesis of arylhydrazines through C?￡?N cross-coupling of aryl chlorides with hydrazine is described. Through the use of continuous flow, the hazards associated with the use of hydrazine in the presence of transition metals are decreased. In addition, multistep flow sequences have also been developed for the generation of functionalized heterocycles utilizing the arylhydrazine intermediates.

Palladium-catalyzed cross-coupling of aryl chlorides and tosylates with hydrazine

Hydrazine is not a problem anymore: The title transformation is the first reaction to yield aryl hydrazines through the cross-coupling of aryl chlorides and tosylates with hydrazine. An appropriately designed palladium catalyst allows this reaction to proceed rapidly under mild conditions, and with excellent chemoselectivity (see scheme; Ad=adamantyl, Ts=4-toluenesulfonyl).

GLUCOCORTICOID RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula I wherein A, n, R1a to R1e and R2 to R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are glucoc

N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action

The synthesis of a series of N-aminoimidazoles (NAIMs) with an uncommon spectrum of antiretroviral activity is described. From a group of 60 closely related molecules, we were able to subdivide the molecules in different groups based on their anti-HIV and anti-SIV activity in vitro: (i) molecules acting on a new, immediate postintegration step, (ii) molecules acting on both postintegration and HIV-1 reverse transcriptase (RT) as NNRTI, and (iii) molecules that mainly act at the HIV-1 RT according to an NNRTI-type mode of action.

Methods of treating neuropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.